I can tell you of a war story of an 18-month delayed charge and award on an ongoing capitated clinical study of a center grant. Bottom line was I had to prove that these were legitimate charges to the funding agency who in turn issued a revised NGA. In other words, work with the funding agency and get their approval. With that, all else will fall in place.
As for the monies, the center grant was capitated clinical multi-studies and we were allowed to use the monies for the other studies of the center grant.
I hope this helps.
J. Felix Gadi
C&G Specialist
Integrative Biology & Pharmacology
The University of Texas Health Science Center at Houston
________________________________
From: Research Administration List on behalf of Linda Ward
Sent: Wed 1/17/2007 11:33 AM
To: xxxxxx@hrinet.org
Subject: [RESADM-L] late cost transfers
We are working on processes for cost transfers, and are seeking your
advice on whether there are exceptions to the 90 day rule:
* Are there justifiable execptions to the 90 day policy?
* If there are justifiable exceptions, who do you have approve them?
* What do you do when a late (over 90 days) cost transfer reduces the
federal obligation (expense) on an award?
* What do you do when a late cost transfer relates only to non
federal
awards - are you more lenient?
* What do you do when a late cost transfer, if not processed,
effectively increases the PI residual on a fixed fee (for example, a
clinical trial) award?
You input is greatly appreciated!!
Linda Ward
Grant Accounting Supervisor
Research Administration 35-123A
Children's Hospitals and Clinics of Minnesota
2910 Centre Pointe Dr.
Roseville, MN 55113
651-855-2603
651-855-2690 Fax
email: xxxxxx@childrensmn.org
_______________________________________________________________
Confidentiality Statement:
This email/fax, including attachments, may include confidential
and/or proprietary information and may be used only by the
person or entity to which it is addressed. If the reader of
this email/fax is not the intended recipient or his or her
agent, the reader is hereby notified that any dissemination,
distribution or copying of this email/fax is prohibited. If you
have received this email/fax in error, please notify the sender
by replying to this message and deleting this email or
destroying this facsimile immediately.
======================================================================
Instructions on how to use the RESADM-L Mailing List, including
subscription information and a web-searchable archive, are available
via our web site at http://www.hrinet.org (click on "Listserv Lists")
======================================================================
======================================================================
Instructions on how to use the RESADM-L Mailing List, including
subscription information and a web-searchable archive, are available
via our web site at http://www.hrinet.org (click on "Listserv Lists")
======================================================================
